For patients with #hemophilia A and B with inhibitors, treatment with #marstacimab effectively reduced estimated annual bleeding rates, declining from 19.8 to 1.4, and significantly improved patients' quality of life by an estimated median of 25.9 points: https://ow.ly/SoLa50Y4z3V
#HemeSky
#Marstacimab ya está aprobado en China para la prevención de sangrados 🩸
👉 Hemofilia A y B
👉 ≥12 años | ≥35 kg
📎 Más información: dengyuemed.com/product/mars...
📧 info@dengyuemed.com
#HYMPAVZI #Hemofilia #DeficienciaDelFactorVIII #DeficienciaDelFactorIX #DengYueMedicinasEnHongKong
EHC issues a Statement on Severe Adverse Event in #Marstacimab #ClinicalTrial.
Read the statement: ehc.eu/news/stateme...
We will continue to follow developments and review any additional information shared by regulatory authorities and Pfizer as the investigation progresses.
Findings from the BASIS trial reveal that #marstacimab is an effective prophylactic option for patients with #hemophilia A and B, as the therapy led to a 92% reduction in mean ABR among patients who previously received on-demand #clotting factors: ow.ly/RIy850WXbGs #HemeSky #hemostasis
The September issue is out now! Highlights include features on the clinician's role in #patient support groups, #marstacimab #prophylaxis for #hemophilia A and B, and post-transplant cyclosporin-cyclophosphamide for #GVHD prevention. See the full lineup: ow.ly/q4zr50WQGOT
Pred kratkim je @ec.europa.eu izdala dovoljenje za promet z novim zdravilom za zdravljenje hemofilije A in B, za bolnike brez inhibitorjev.
haemophamicus.eu/blog/marstac...
#marstacimab #hemofilija #zdravljenje #motnjestrjevanjakrvi #novosti #odobritev #preprečevanjekrvavitev @eahad.bsky.social
